Brief: FDA Grants RMAT Designation for enGene’s Detalimogene
25/06/2025 13:28
June 25 (Reuters) - enGene Holdings Inc ENGN.O: FDA GRANTS RMAT DESIGNATION FOR ENGENE’S DETALIMOGENE, ENABLING POTENTIAL FOR EXPEDITED REVIEW IN HIGH-RISK, NON-MUSCLE INVASIVE BLADDER CANCER Source text: ID:nBw2rHRbma Further company coverage: ENGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on enGene Therapeutics
See all newsBrief: Engene Reports Second Quarter 2026 Financial Results And Provides Business Update
enGene Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Engene Holdings Inc - To Change Name To Engene Therapeutics Inc. Effective April 8, 2026
Brief: Engene Holdings Enters Sales Agreement With Leerink Partners To Sell Common Shares
Brief: enGene Reports First Quarter 2026 Financial Results and Provides Business Update